multiple sclerosis

Ocrelizumab for Multiple Sclerosis
Ocrelizumab for Multiple SclerosisThe FDA has approved ocrelizumab for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
Medical marijuana update: Top 3 things health execs should knowHere’s what you need to know about medical marijuana laws, and what they mean for the healthcare system.
FDA approves Bayer’s Bluetooth-enabled auto-injector for multiple sclerosisFDA has approved a supplemental Biologics License Application (sBLA) for Bayer’s myBETAapp and BETACONNECT Navigator for multiple sclerosis (MS) patients
10 More Newly Approved Drugs
10 More Newly Approved DrugsWhat you need to know about the the 10 newest FDA drug approvals.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Copay assistance programs: Managed care pros and consDo copay assistance program offer a long-term solution for patients? Experts weigh in.
FDA approves Zinbryta to treat multiple sclerosisFDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).
Electronic prior authorization and payers: Lessons from BCBSTwo presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
Shaping specialty pharmacy’s future: 4 perspectivesAt AMCP, four stakeholders representing the specialty pharmacy perspective, manufacturer perspective, payer perspective, and PBM perspective shared their thoughts on the future of specialty pharmacy.